MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Legend Biotech Corp ADR

Închisă

SectorSănătate

33.29 5.75

Rezumat

Modificarea prețului

24h

Curent

Minim

30.96

Maxim

33.51

Indicatori cheie

By Trading Economics

Venit

161M

41M

Vânzări

26M

187M

EPS

0.14

Marjă de profit

21.719

Angajați

2,600

EBITDA

162M

52M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+164.47% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-30M

6.4B

Deschiderea anterioară

27.54

Închiderea anterioară

33.29

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Legend Biotech Corp ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 mai 2024, 11:36 UTC

Câștiguri

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 mar. 2025, 11:09 UTC

Câștiguri

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mar. 2025, 11:08 UTC

Câștiguri

Legend Biotech 4Q EPS 7c >LEGN

11 mar. 2025, 11:00 UTC

Câștiguri

Legend Biotech 4Q Rev $186.5M >LEGN

12 nov. 2024, 12:06 UTC

Câștiguri

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 nov. 2024, 12:05 UTC

Câștiguri

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 nov. 2024, 12:00 UTC

Câștiguri

Legend Biotech 3Q Rev $160.2M >LEGN

9 aug. 2024, 11:02 UTC

Câștiguri

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 aug. 2024, 11:01 UTC

Câștiguri

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 aug. 2024, 11:01 UTC

Câștiguri

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 aug. 2024, 11:00 UTC

Câștiguri

Legend Biotech 2Q Rev $186.5M >LEGN

26 iul. 2024, 11:01 UTC

Câștiguri

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 mai 2024, 11:02 UTC

Câștiguri

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 mai 2024, 11:02 UTC

Câștiguri

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Comparație

Modificare preț

Legend Biotech Corp ADR Așteptări

Obiectiv de preț

By TipRanks

164.47% sus

Prognoză pe 12 luni

Medie 83.36 USD  164.47%

Maxim 95 USD

Minim 62 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLegend Biotech Corp ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

13

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

31.39 / 35.05Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.